Ambrisentan: Safety and Efficacy in the Treatment of Eisenmenger Syndrome.

Rowan, CA; Lederer, Dieter; Ks, Lee; Rosenzweig, E.B.

doi:10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a4919

Search citation statements

Order By: Relevance

Paper Sections

Select...

Monitoring Recommendations1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2011

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[28] In evaluable patients at follow-up, 6MWD was significantly longer than at baseline (401 vs 370 m; p < 0.009), WHO functional class was maintained in all patients (3 patients improved from baseline and 12 remained stable) and systemic arterial oxygen saturation remained stable relative to baseline (90% vs 91%). In a retrospective chart review, 15 patients with Eisenmenger syndrome received treatment with ambrisentan for at least 3 months (average 188 days); 8 patients had previously received either sitaxentan or bosentan, and 14 were receiving a PDE-5 inhibitor or iloprost at baseline.…”

Section: Monitoring Recommendationsmentioning

confidence: 84%